{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019633","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.503570+00:00","generated_at":"2026-06-15T08:33:38.521217+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma reports Q1 2023 cash of $117.6M; Phase 3 sarcoidosis trial enrolling","bullets":["Cash, equivalents and investments of $117.6M as of March 31, 2023; $48.1M net from February stock offering.","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling in U.S., Europe and Japan; up to 264 subjects.","Phase 2 proof-of-concept study in SSc-ILD expected to initiate Q3 2023; 25 patients, multiple U.S. centers.","R&D expenses $9.4M and G&A expenses $3.4M for Q1 2023; cash runway projected into 2026.","Multiple efzofitimod presentations planned at ATS 2023 International Conference May 19-24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019633","json":"https://secwatch.observer/filing/0000950170-23-019633.json","markdown":"https://secwatch.observer/filing/0000950170-23-019633.md","text":"https://secwatch.observer/filing/0000950170-23-019633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/0000950170-23-019633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/life-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:33:38.521217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61da51ecf3991c77c757cb6f0327416fd42ad180","claim":"aTYR PHARMA INC updated its three months ended March 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On May 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/0000950170-23-019633-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}